What makes certain neuronal populations vulnerable to 90% loss while others are spared in AD?

OPEN

The abstract mentions that neuronal loss can exceed 90% in vulnerable populations but doesn't explain the basis for this selective vulnerability. Identifying these protective/risk factors could reveal new therapeutic targets and biomarkers. Gap type: unexplained_observation Source paper: Oxidative stress and neurodegeneration. (2005, Annals of the New York Academy of Sciences, PMID:16037277)

Priority: 0.82 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: What makes certain neuronal populations vulnerable to 90% loss while others are spared in AD? is a 0.82 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What makes certain neuronal populations vulnerable to 90% loss while others are spared in AD? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (21)

entities-atp7b-geneADentities-rosADentities-histone-methylationADTAUADTDP-43AD
▸ Show 16 more

biomarker for (1)

tau cleavage productsAD

causes (6)

ADneurodegenerationPHOSPHORYLATED_TAUADBETA_AMYLOIDADADmemory_lossADIMMUNE_TOL
▸ Show 1 more

contributes to (1)

NEUROINFLAMMATIONAD

cross disease mechanism in (5)

MAPTADTREM2ADNLRP3ADPINK1ADGRNAD

depleted in (1)

SPM_levelsAD

prevents (1)

NAD+ augmentationAD

protective against (1)

cognitive stimulationAD

regulates (1)

ADPROTEOME

risk factor for (4)

genetically at-risk individualsADAPOE ε4ADmicroglial primingADAPOE4AD

targets (1)

resveratrolAD

therapeutic target for (6)

CCR2ADTREM2ADSaracatinibADanti-amyloid antibodiesADNAD+ augmentationAD
▸ Show 1 more

treats (1)

HTL9936AD
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps